Download PDF
Thromb Haemost 2022; 122(04): 611-622
DOI: 10.1055/s-0041-1733800
Stroke, Systemic or Venous Thromboembolism

Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells

Miruna Popa
1   Division of Cardiovascular Physiology, Institute of Physiology and Pathophysiology, Heidelberg University, Heidelberg, Germany
,
Markus Hecker
1   Division of Cardiovascular Physiology, Institute of Physiology and Pathophysiology, Heidelberg University, Heidelberg, Germany
,
Andreas H. Wagner
1   Division of Cardiovascular Physiology, Institute of Physiology and Pathophysiology, Heidelberg University, Heidelberg, Germany
› Author Affiliations Funding This work was supported by a grant from the Deutsche Forschungsgemeinschaft (TRR 23 project sections C6) and internal funds.
› Further Information
    Permissions and Reprints

Abstract

ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a zinc-containing metalloprotease also known as von Willebrand factor (vWF)-cleaving protease. Low ADAMTS13 plasma levels are associated with an increased risk of arterial thrombosis, including myocardial infarction and cerebrovascular disease. The expression and regulation of this metalloprotease in human endothelial cells have not been systematically investigated. In this study, we demonstrate that ADAMTS13 expression is inhibited by proinflammatory cytokines tumor necrosis factor-α and interferon-γ as well as by CD40 ligand, which was hitherto unknown. Factors protecting against atherosclerosis such as exposure to continuous unidirectional shear stress, interleukin-10, or different HMG-CoA reductase inhibitors like, e.g., simvastatin, atorvastatin, or rosuvastatin, did not influence ADAMTS13 expression. Unidirectional periodic orbital shear stress, mimicking oscillatory flow conditions found at atherosclerosis-prone arterial bifurcations, had also no effect. In contrast, a reciprocal correlation between ADAMTS13 and vWF expression in endothelial cells depending on the differentiation state was noted. ADAMTS13 abundance significantly rose on both the mRNA and intracellular protein level and also tethered to the endothelial glycocalyx with the degree of confluency while vWF protein levels were highest in proliferating cells but significantly decreased upon reaching confluence. This finding could explain the anti-inflammatory and antithrombotic phenotype of dormant endothelial cells mediated by contact inhibition.

Keywords

ADAMTS13 - CD40 - endothelial cells - von Willebrand factor

Supplementary Material



Publication History

Received: 03 December 2020

Accepted: 28 June 2021

Article published online:
05 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276 (44) 41059-41063
    CrossrefPubMedGoogle Scholar
  • 2 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424
    CrossrefPubMedGoogle Scholar
  • 3 Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3 (08) 1710-1716
    CrossrefPubMedGoogle Scholar
  • 4 Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98 (09) 2730-2735
    CrossrefPubMedGoogle Scholar
  • 5 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307 (23) 1432-1435
    CrossrefPubMedGoogle Scholar
  • 6 Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 2015; 113 (04) 708-718
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Popa M, Tahir S, Elrod J. et al. Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction. Proc Natl Acad Sci U S A 2018; 115 (24) E5556-E5565
    CrossrefPubMedGoogle Scholar
  • 8 Sonneveld MA, Kavousi M, Ikram MA. et al. Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study. J Thromb Haemost 2016; 14 (11) 2114-2120
    CrossrefPubMedGoogle Scholar
  • 9 Gandhi C, Khan MM, Lentz SR, Chauhan AK. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood 2012; 119 (10) 2385-2391
    CrossrefPubMedGoogle Scholar
  • 10 De Meyer SF, Savchenko AS, Haas MS. et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood 2012; 120 (26) 5217-5223
    CrossrefPubMedGoogle Scholar
  • 11 Tahir S, Wagner AH, Dietzel S. et al. Endothelial CD40 mediates microvascular von Willebrand factor-dependent platelet adhesion inducing inflammatory venothrombosis in ADAMTS13 knockout mice. Thromb Haemost 2020; 120 (03) 466-476
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Rodgers GM. ed. ADAMTS13 Biology and Disease. 1st ed.. Cham: Springer International Publishing; 2015
    CrossrefGoogle Scholar
  • 13 Bauer AT, Suckau J, Frank K. et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood 2015; 125 (20) 3153-3163
    CrossrefPubMedGoogle Scholar
  • 14 Wagner AH, Güldenzoph B, Lienenlüke B, Hecker M. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol 2004; 24 (04) 715-720
    CrossrefPubMedGoogle Scholar
  • 15 Schubert A, Cattaruzza M, Hecker M, Darmer D, Holtz J, Morawietz H. Shear stress-dependent regulation of the human beta-tubulin folding cofactor D gene. Circ Res 2000; 87 (12) 1188-1194
    CrossrefPubMedGoogle Scholar
  • 16 Baudin B, Bruneel A, Bosselut N, Vaubourdolle M. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protoc 2007; 2 (03) 481-485
    CrossrefPubMedGoogle Scholar
  • 17 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29 (09) e45
    CrossrefPubMedGoogle Scholar
  • 18 Wagner AH, Hildebrandt A, Baumgarten S. et al. Tyrosine nitration limits stretch-induced CD40 expression and disconnects CD40 signaling in human endothelial cells. Blood 2011; 118 (13) 3734-3742
    CrossrefPubMedGoogle Scholar
  • 19 Toth M, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9 by gelatin zymography. Methods Mol Med 2001; 57: 163-174
    PubMedGoogle Scholar
  • 20 Möller K, Adolph O, Grünow J. et al. Mechanism and functional impact of CD40 ligand-induced von Willebrand factor release from endothelial cells. Thromb Haemost 2015; 113 (05) 1095-1108
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Kwak BR, Bäck M, Bochaton-Piallat ML. et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur Heart J 2014; 35 (43) 3013-3020
    CrossrefPubMedGoogle Scholar
  • 22 Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011; 91 (01) 327-387
    CrossrefPubMedGoogle Scholar
  • 23 Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6 (12) 1399-1402
    CrossrefPubMedGoogle Scholar
  • 24 Nissen SE, Tuzcu EM, Schoenhagen P. et al; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352 (01) 29-38
    CrossrefPubMedGoogle Scholar
  • 25 Shen L, Lu G, Dong N, Ma Z, Ruan C. Simvastatin increases ADAMTS13 expression in podocytes. Thromb Res 2013; 132 (01) 94-99
    CrossrefPubMedGoogle Scholar
  • 26 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81 (01) 8-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Galbiati F, Volonte D, Engelman JA. et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998; 17 (22) 6633-6648
    CrossrefPubMedGoogle Scholar
  • 28 Caveda L, Martin-Padura I, Navarro P. et al. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). J Clin Invest 1996; 98 (04) 886-893
    CrossrefPubMedGoogle Scholar
  • 29 Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol 2008; 28 (02) 223-232
    CrossrefPubMedGoogle Scholar
  • 30 Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104 (01) 100-106
    CrossrefPubMedGoogle Scholar
  • 31 Frostegård J, Ulfgren AK, Nyberg P. et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145 (01) 33-43
    CrossrefPubMedGoogle Scholar
  • 32 Manicourt D-H, Triki R, Fukuda K, Devogelaer JP, Nagant de Deuxchaisnes C, Thonar EJ. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993; 36 (04) 490-499
    CrossrefPubMedGoogle Scholar
  • 33 Spranger J, Kroke A, Möhlig M. et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52 (03) 812-817
    CrossrefPubMedGoogle Scholar
  • 34 Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond) 2010; 7: 29
    CrossrefPubMedGoogle Scholar
  • 35 Pinderski LJ, Fischbein MP, Subbanagounder G. et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90 (10) 1064-1071
    CrossrefPubMedGoogle Scholar
  • 36 Ortego M, Bustos C, Hernández-Presa MA. et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147 (02) 253-261
    CrossrefPubMedGoogle Scholar
  • 37 Claus RA, Bockmeyer CL, Kentouche K. et al. Transcriptional regulation of ADAMTS13. Thromb Haemost 2005; 94 (01) 41-45
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 2008; 6 (07) 1233-1235
    CrossrefPubMedGoogle Scholar
  • 39 Mach F, Schönbeck U, Fabunmi RP. et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154 (01) 229-238
    CrossrefPubMedGoogle Scholar
  • 40 Matsukawa M, Kaikita K, Soejima K. et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 2007; 100 (05) 758-763
    CrossrefPubMedGoogle Scholar
  • 41 Reiter RA, Varadi K, Turecek PL, Jilma B, Knöbl P. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005; 93 (03) 554-558
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Turner NA, Nolasco L, Ruggeri ZM, Moake JL. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 2009; 114 (24) 5102-5111
    CrossrefPubMedGoogle Scholar
  • 43 Risau W. Mechanisms of angiogenesis. Nature 1997; 386 (6626): 671-674
    CrossrefPubMedGoogle Scholar
  • 44 Yang X, Sun HJ, Li ZR. et al. Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer 2015; 15: 80
    CrossrefPubMedGoogle Scholar
  • 45 Blann AD. Increased release of von Willebrand factor antigen by endothelial cells whilst in active growth phase. Cell Biol Int Rep 1991; 15 (06) 493-498
    CrossrefPubMedGoogle Scholar
  • 46 Shang D, Zheng XW, Niiya M, Zheng XL. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108 (07) 2207-2215
    CrossrefPubMedGoogle Scholar
  • 47 Majerus EM, Zheng X, Tuley EA, Sadler JE. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 2003; 278 (47) 46643-46648
    CrossrefPubMedGoogle Scholar
  • 48 Vomund AN, Majerus EM. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem 2009; 284 (45) 30925-30932
    CrossrefPubMedGoogle Scholar
  • 49 Adams JC, Tucker RP. The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development. Dev Dyn 2000; 218 (02) 280-299
    CrossrefPubMedGoogle Scholar
  • 50 Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ Res 2003; 93 (10) e136-e142
    CrossrefPubMedGoogle Scholar
  • 51 Kiyan Y, Tkachuk S, Kurselis K. et al. Heparanase-2 protects from LPS-mediated endothelial injury by inhibiting TLR4 signalling. Sci Rep 2019; 9 (01) 13591
    CrossrefPubMedGoogle Scholar
  • 52 Butler MJ, Down CJ, Foster RR, Satchell SC. The pathological relevance of increased endothelial glycocalyx permeability. Am J Pathol 2020; 190 (04) 742-751
    CrossrefPubMedGoogle Scholar
  • 53 Kolářová H, Ambrůzová B, Svihálková Šindlerová L, Klinke A, Kubala L. Modulation of endothelial glycocalyx structure under inflammatory conditions. Mediators Inflamm 2014; 2014: 694312
    CrossrefPubMedGoogle Scholar
  • 54 Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101 (03) 946-948
    CrossrefPubMedGoogle Scholar
  • 55 Löwenberg EC, Charunwatthana P, Cohen S. et al. Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thromb Haemost 2010; 103 (01) 181-187
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Miura M, Kaikita K, Matsukawa M. et al. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost 2010; 103 (03) 623-629
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Bouïs D, Hospers GA, Meijer C, Molema G, Mulder NH. Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis 2001; 4 (02) 91-102
    CrossrefPubMedGoogle Scholar